Nesina (nes-SEE-na, alogliptin) will compete in a crowded market of gliptins, or DPP-4 inhibitors, for type 2 diabetes
Nesina (nes-SEE-na, alogliptin) will compete in a crowded market of gliptins, or DPP-4 inhibitors, for type 2 diabetes.
It's a "me too"...similar to Januvia (sitagliptin), Onglyza (saxagliptin), and Tradjenta (linagliptin).
Continue to recommend lifestyle changes and metformin first.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote